Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy for soft tissue sarcoma.

M J Greenall, G B Magill, J J DeCosse

    Surgery, Gynecology & Obstetrics
    |February 1, 1986
    PubMed
    Summary

    Adriamycin remains the sole effective single agent for metastatic sarcoma. New combination chemotherapy regimens require rigorous evaluation to improve patient outcomes, as current options show limited efficacy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Debulking of a gastrointestinal hemangioma alleviates coagulopathy associated with Kasabach-Merritt syndrome.

    Surgery·1999
    Same author

    Colonoscopic diagnosis of grumbling appendicitis.

    Lancet (London, England)·1998
    Same author

    Quality of life.

    Journal of surgical oncology·1997
    Same author

    Depth of invasion of colon carcinoma, lymphatic spread, and laparoscopic surgery.

    Cancer·1997
    Same author

    Quality-of-life management of patients with colorectal cancer.

    CA: a cancer journal for clinicians·1997
    Same author

    Re: A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer.

    Journal of the National Cancer Institute·1996

    Area of Science:

    • Medical Oncology
    • Pharmacology
    • Clinical Trials

    Background:

    • Adriamycin is the only effective single agent for metastatic sarcoma.
    • Combination chemotherapy regimens omitting Adriamycin are ineffective in adults.
    • Current regimens like CYVADIC show diminishing efficacy, necessitating new approaches.

    Purpose of the Study:

    • To highlight the need for evaluating novel chemotherapy regimens in metastatic sarcoma.
    • To emphasize the importance of prospective, randomized studies for new treatments.
    • To advocate for standardized response criteria and inclusion of prognostic variables.

    Main Methods:

    • Review of existing chemotherapy efficacy in metastatic sarcoma.
    • Identification of limitations in current treatment protocols.
    • Proposal for future research methodologies.

    Main Results:

    • No combination chemotherapy has consistently outperformed CYVADIC.
    • Complete response rates with existing regimens are below 15%.
    • Doubts exist regarding the efficacy of previously successful regimens like CYVADIC.

    Conclusions:

    • There is a critical need for further evaluation of new chemotherapy regimens.
    • Prospective, randomized studies with consistent response criteria are essential.
    • Analysis of prognostic variables could identify patients likely to have poor outcomes.

    Related Experiment Videos